BACKGROUND: Dementia with Lewy Bodies (DLB) can be difficult to distinguish clinically from other dementias. OBJECTIVE: To investigate the diagnostic utility of CSF alpha-synuclein in differentiating between DLB and other dementias. METHODS: Electronic databases were systematically searched for studies investigating reproducible alpha synuclein quantification methods. Random effects model was used to calculate weighted mean difference (WMD) and 95% confidence intervals between DLB and other groups. RESULTS: A total of 13 studies, comprising 2728 patients were included. Mean CSF alpha-synuclein concentration was significantly lower in DLB patients compared to those with Alzheimers disease (AD) [WMD -0.24; 95% CI, -0.45, -0.03; p = 0.02]. No significant difference was found between patients with DLB compared to Parkinsons disease [WMD 0.05; 95% CI, -0.17, 0.28; p = 0.65] or other neurodegenerative conditions. CONCLUSION: CSF alpha synuclein may be of diagnostic use in differentiating between DLB and AD. We propose several recommendations to guide better design of future studies.
BACKGROUND:Dementia with Lewy Bodies (DLB) can be difficult to distinguish clinically from other dementias. OBJECTIVE: To investigate the diagnostic utility of CSF alpha-synuclein in differentiating between DLB and other dementias. METHODS: Electronic databases were systematically searched for studies investigating reproducible alpha synuclein quantification methods. Random effects model was used to calculate weighted mean difference (WMD) and 95% confidence intervals between DLB and other groups. RESULTS: A total of 13 studies, comprising 2728 patients were included. Mean CSF alpha-synuclein concentration was significantly lower in DLB patients compared to those with Alzheimers disease (AD) [WMD -0.24; 95% CI, -0.45, -0.03; p = 0.02]. No significant difference was found between patients with DLB compared to Parkinsons disease [WMD 0.05; 95% CI, -0.17, 0.28; p = 0.65] or other neurodegenerative conditions. CONCLUSION: CSF alpha synuclein may be of diagnostic use in differentiating between DLB and AD. We propose several recommendations to guide better design of future studies.
Authors: R Scott Mackin; Philip Insel; Jing Zhang; Brian Mohlenhoff; Douglas Galasko; Michael Weiner; Niklas Mattsson Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472
Authors: Ruth A Cromarty; Greg J Elder; Sara Graziadio; Mark Baker; Laura Bonanni; Marco Onofrj; John T O'Brien; John-Paul Taylor Journal: Clin Neurophysiol Date: 2015-06-27 Impact factor: 3.708
Authors: Niels Kruse; Amanda Heslegrave; Vandana Gupta; Martha Foiani; Anna Villar-Piqué; Matthias Schmitz; Sylvain Lehmann; Charlotte Teunissen; Kaj Blennow; Henrik Zetterberg; Brit Mollenhauer; Inga Zerr; Franc Llorens Journal: Alzheimers Dement (Amst) Date: 2018-07-07
Authors: Inger van Steenoven; Nour K Majbour; Nishant N Vaikath; Henk W Berendse; Wiesje M van der Flier; Wilma D J van de Berg; Charlotte E Teunissen; Afina W Lemstra; Omar M A El-Agnaf Journal: Mov Disord Date: 2018-11-15 Impact factor: 10.338